Lin Fan, Chen Bin-Ling, Wang Yi-Zheng, Gao Dong, Song Jun, Kaptchuk T J, Chen Ke-Ji
College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
The Second Hospital of Longyan, Longyan, Fujian Province, 364000, China.
Chin J Integr Med. 2018 Aug;24(8):606-612. doi: 10.1007/s11655-015-2289-9. Epub 2015 Aug 14.
To compare the angiogenesis behaviors of vascular endothelial growth factor (VEGF) and Chinese medicine Xuefu Zhuyu Decoction (, XZD) treatments.
Human microvascular endothelial cells (HMEC-1) were treated with various concentrations of either XZD-containing serum (XZD-CS) or VEGF for 24, 48, and 72 h, respectively. Cell viability, proliferation, migration, adhesion, and in vitro tube formation assays were used to assess their angiogenic effects.
VEGF promoted all cellular phases involved in angiogenesis including cell viability, proliferation, migration, adhesion, and tube formation (<0.05 or <0.01). Unlike the continuous promotion effects of VEGF at the above stages, XZD inhibited cell viability and proliferation (<0.05 or <0.01) and only promoted tube formation in the early phase of angiogenesis (<0.01).
These two medications promote different angiogenesis behaviors, which might be an important reason for their distinct therapeutic profile in clinical usage.
比较血管内皮生长因子(VEGF)与中药血府逐瘀汤(XZD)治疗的血管生成行为。
分别用不同浓度含XZD血清(XZD-CS)或VEGF处理人微血管内皮细胞(HMEC-1)24、48和72小时。采用细胞活力、增殖、迁移、黏附及体外管腔形成实验评估其血管生成作用。
VEGF促进血管生成涉及的所有细胞阶段,包括细胞活力、增殖、迁移、黏附及管腔形成(<0.05或<0.01)。与VEGF在上述阶段的持续促进作用不同,XZD抑制细胞活力和增殖(<0.05或<0.01),且仅在血管生成早期促进管腔形成(<0.01)。
这两种药物促进不同的血管生成行为,这可能是它们在临床应用中具有不同治疗效果的重要原因。